SS&C’s (NASDAQ:SSNC) Q1 Sales Beat Estimates But Quarterly Revenue Guidance Slightly Misses Expectations
  • April 24, 2025

SS&C’s (NASDAQ:SSNC) Q1 Sales Beat Estimates But Quarterly Revenue Guidance Slightly Misses Expectations

Financial software provider SS&C Technologies (NASDAQ:SSNC) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.4% year on year to $1.51 billion. On the other hand, next quarter’s revenue guidance of $1.51 billion was less impressive, coming in 1.4% below analysts’ estimates. Its non-GAAP profit of $1.44 per share was 2.4% above analysts’ consensus estimates.

Universal Logistics (NASDAQ:ULH) Misses Q1 Revenue Estimates
  • April 24, 2025

Universal Logistics (NASDAQ:ULH) Misses Q1 Revenue Estimates

Transportation and logistics solutions provider Universal Logistics (NASDAQ:ULH) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 22.3% year on year to $382.4 million. Its GAAP profit of $0.23 per share was 52.1% below analysts’ consensus estimates.

Alphabet’s (NASDAQ:GOOGL) Q1: Beats On Revenue
  • April 24, 2025

Alphabet’s (NASDAQ:GOOGL) Q1: Beats On Revenue

Online advertising giant Alphabet (NASDAQ:GOOGL) announced better-than-expected revenue in Q1 CY2025, with sales up 12% year on year to $90.23 billion. Its GAAP profit of $2.81 per share was 40.1% above analysts’ consensus estimates.

Intel (NASDAQ:INTC) Q1 Sales Beat Estimates But Stock Drops
  • April 24, 2025

Intel (NASDAQ:INTC) Q1 Sales Beat Estimates But Stock Drops

Computer processor maker Intel (NASDAQ:INTC) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $12.67 billion. On the other hand, next quarter’s revenue guidance of $11.8 billion was less impressive, coming in 8.4% below analysts’ estimates. Its non-GAAP profit of $0.13 per share was significantly above analysts’ consensus estimates.

Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates
  • April 24, 2025

Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts’ consensus estimates.